A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (“MASH”), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. MASH was previously known as nonalcoholic steatohepatitis (“NASH”). MASH is the leading cause of liver transplantation in women, the second leading cause of all liver transplantation in the United States and the fastest-growing indication for liver transplantation in Europe. Our medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta (“THR-β”) agonist designed to target key underlying causes of MASH. In March 2024, Rezdiffra became the first therapy approved by the FDA for patients with MASH and was commercially available in the United States beginning in April 2024.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 958M | 958M | - | 0 | 0 | 0 |
| Net Income | -288M | -288M | -466M | -374M | -295M | -242M |
| EPS | $-12.85 | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 |
| Free Cash Flow | -190M | -190M | -457M | -326M | -225M | -184M |
| ROIC | -31.9% | -30.6% | -53.4% | -71.7% | -64.0% | -97.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.56 | 0.56 | 0.16 | 0.28 | 0.25 | 0.39 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -300M | -300M | -498M | -380M | -294M | -242M |
| Operating Margin | -31.3% | -31.3% | - | - | - | - |
| ROE | -47.8% | -42.5% | -61.8% | -92.2% | -149.6% | -110.9% |
| Shares Outstanding | 22M | 22M | 21M | 19M | 17M | 17M |
MADRIGAL PHARMACEUTICALS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -24.3%.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a 5-year average return on invested capital (ROIC) of -63.5%. This is below average and may indicate limited pricing power.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a market capitalization of $11.8B. It is classified as a large-cap stock.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) does not currently pay a regular dividend.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported annual revenue of $958 million in its most recent fiscal year, based on SEC EDGAR filings.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a net profit margin of -30.1%. The company is currently unprofitable.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) generated $-190 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a debt-to-equity ratio of 0.56. This indicates moderate leverage.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported earnings per share (EPS) of $-12.85 in its most recent fiscal year.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a return on equity (ROE) of -42.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for MADRIGAL PHARMACEUTICALS, INC. (MDGL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a book value per share of $26.86, based on its most recent annual SEC filing.